Well here we are with another positive announcement (we won’t quibble on whether it should be price sensitive or not).
So what is the state of play as we look at near on a 12 month low in the share price.
Quantity of products
We have 3 products in human clinical trials with a fourth being used for a trial preoperative in the UK.- TICK.
Quality of products
We have Azer-cel with and IND, ONCARlyTics with an IND, and Vaxinia with an IND, FAST TRACK, and ODD.-TICK
We have HERVACC which has completed Phase 2 trial with results similar to that of an FDA approved drug which is coming to an end of its Patent protection.
All data readouts to date have been excellent with an enviable safety record.-TICK
Patent protection
We have long Patent protection through to 2040 in multiple markets.-TICK
Financials
We have sufficient funds to cover above trials for up to 12 Months.-TICK
Management
We have very good stable management, with little turmoil or changeover to key positions.-TICK
Board
The board are laser focused on making decisions in the interests of the company, supporting management in operational decisions, and as with management reasonably stable positions.- TICK
Of course much of what is written above includes my opinion so take it with a grain of salt as with all anonymous opinions.
DYOR opinion only
(20min delay)